Pfizer lifted its annual earnings forecast on Wednesday and reported a first-quarter profit above Wall Street estimates, ...

Pfizer's strategic weaknesses mount and the stock became overvalued after the recent rally. Read more to see our analysis on ...

Pfizer reported first-quarter revenue that beat expectations and hiked its full-year profit outlook, benefiting from its ...

Andrew Baum, the prominent Wall Street drug company analyst will be the pharma firm’s chief strategy and innovation officer.

Andrew Baum has worked at Citi since 2011 following a 14-year stint at Morgan Stanley, where he covered European ...

Pfizer Inc. (PFE) announced that Andrew Baum will be the new Chief Strategy and Innovation Officer, Executive Vice President, ...

Citi analyst Andrew Baum, after covering Pfizer for more than a decade, will join the Big Pharma company as chief strategy and innovation officer. In the role, he'll oversee the drugmaker's portfolio ...

AM Best has confirmed the financial strength rating of A (Excellent) and the long-term issuer credit rating of a+ (Excellent) ...

By Colin Kellaher Pfizer had hired Andrew Baum as the drugmaker's next chief strategy and innovation officer. Pfizer on Monday said Baum, who has been ...

Physicians are unequivocal about who is the big kahuna in the vaccine industry. | Physicians are unequivocal about who is the ...

Pfizer reports Q1 results: adjusted EPS beats estimates, driven by revenue growth. Significant declines in Comirnaty and ...

Where there's a will, there's a way. And Pfizer appears to have the will to stake a claim in the massive obesity drug market.